Market Today: CRISPR Therapeutics and Vertex Pharmaceuticals Make History with UK Drug Approval
The gene editing sector experienced a significant shakeup as CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) received UK approval for their groundbreaking CRISPR-based drug exa-cel, designed to treat sickle cell disease and beta-thalassemia. This historic approval sent…
#crisprtherapeutics #vrtx #crispr #maxcyte #mxct #graphitebio #precisionbiosciences #dtil #editasmedicine #beamtherapeutics